Akèy › Kansè renn (Kasinom selil renn) › Tennessee › Nashville
Etid klinik pou Kansè renn (Kasinom selil renn) nan Nashville, TN
23 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Ap rekriteFaz 1
- Research Site, Nashville
- Research Site, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center ( Site 5004), Nashville
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI), Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #3, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Vanderbilt University Medical Center, Nashville
Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
- ak 11 plis
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Ap rekriteFaz 2
- Vanderbilt-Ingram Cancer Center, Nashville
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Ap rekriteFaz 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Ap rekriteFaz 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1
- Xencor Investigative Site, Nashville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- SCRI - Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Ap rekrite
- Vanderbilt-Ingram Cancer Center, Nashville
Etid Kansè renn (Kasinom selil renn) nan lòt vil
- Houston, TX35 etid
- New York City, NY27 etid
- Dallas, TX23 etid
- St. Louis, MO23 etid
- Los Angeles, CA20 etid
- Boston, MA16 etid
- Baldwin Park, CA16 etid
- Philadelphia, PA15 etid
- Pittsburgh, PA15 etid
- Queens, NY15 etid
- Jacksonville, FL14 etid
- Cleveland, OH14 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.